Role of CD146 (MCAM) in Physiological and Pathological Angiogenesis—Contribution of New Antibodies for Therapy
Ahmad Joshkon, Xavier Heim, Cléa Dubrou, Richard Bachelier, Waël Traboulsi, Jimmy Stalin, Hussein Fayyad‐Kazan, Bassam Badran, Alexandrine Foucault‐Bertaud, Aurélie S. Leroyer, Nathalie Bardin, Marcel Blot‐Chabaud
Abstract
The fundamental role of cell adhesion molecules in mediating various biological processes as angiogenesis has been well-documented. CD146, an adhesion molecule of the immunoglobulin superfamily, and its soluble form, constitute major players in both physiological and pathological angiogenesis. A growing body of evidence shows soluble CD146 to be significantly elevated in the serum or interstitial fluid of patients with pathologies related to deregulated angiogenesis, as autoimmune diseases, obstetric and ocular pathologies, and cancers. To block the undesirable effects of this molecule, therapeutic antibodies have been developed. Herein, we review the multifaceted functions of CD146 in physiological and pathological angiogenesis and summarize the interest of using monoclonal antibodies for therapeutic purposes.